Arcella Bio Company Profile

Background

Arcella Bio, founded in 2017, is a Netherlands-based company specializing in computational life sciences. The company is dedicated to transforming biomedical data into actionable insights, aiming to enhance patient outcomes and accelerate drug discovery processes. By integrating data collection, innovative analytics, and intelligent insights, Arcella Bio seeks to redefine personalized medicine and streamline drug development.

Key Strategic Focus

Arcella Bio's strategic focus encompasses:

Patient Empowerment: Development of applications that enable patients to manage, store, and comprehend their medical data, thereby fostering informed decision-making.

Data Analytics Platform: Provision of data analysis and actionable insights addressing critical business questions in the biopharmaceutical industry, including drug combinations, indication expansion, and patient responder analysis.

Scientific Research Engine: Offering powerful text and figure search capabilities to deliver fast and accurate results for researchers.

Market and Competitor Intelligence: Providing analytics on market players and product users to inform strategic decisions.

API Access: Granting access to structured biomedical data sources for developers and researchers.

Financials and Funding

Arcella Bio has participated in multiple accelerator and incubator programs, reflecting its commitment to growth and innovation. Notable funding milestones include:

February 2024: Completed an accelerator/incubator round.

March 2022: Participated in an accelerator/incubator program.

June 2020: Engaged in an accelerator/incubator initiative.

January 2020: Joined an accelerator/incubator program.

November 2019: Received a grant.

January 2018: Secured seed funding.

October 2017: Participated in an accelerator/incubator program.

February 2017: Received a grant of $214,000.

These funding rounds have been instrumental in advancing Arcella Bio's technological platforms and expanding its product offerings.

Pipeline Development

Arcella Bio's key developments include:

Colorectal Cancer Patient App: A comprehensive application designed to empower patients by providing insights into their medical records, information on drug therapy side effects, scientific evidence based on mutations, access to second opinion doctors, clinical trial matching, and a community forum. This initiative is co-funded and supported by the European Commission and close advocates.

Research Collaboration: Partnership with an innovative EU start-up to discover new combination therapies for colorectal cancer, including testing existing blockbuster drugs for multiple myeloma in combination with nuclear export inhibitors, showing effectiveness in destroying colorectal cancer cells from fresh patient-biopsy derived cells.

Technological Platform and Innovation

Arcella Bio's technological innovations include:

Biomedical Data Infrastructure: A robust infrastructure enabling rapid extraction from extensive biomedical literature, resulting in accurate analyses. The platform encompasses over 6 billion scientific publication sentences, 20 million figures, and 40 million scientific publications.

Scientific Research Engine: Features include biomedical entity recognition, natural language processing analysis, customizable text search, author search, and biomedical figure and image analysis.

Market and Competitor Intelligence: Provides analytics on products, locations, competitors, and user contact information.

API Access: Offers secure cloud API solutions with 99.9% uptime capability, granting access to raw biomedical data.

Leadership Team

Anna O'Leary: Co-founder & CEO. With a background in Economics and Finance and experience in investment banking, Anna transitioned into the Life Science industry eight years ago. She was part of the first agency to distribute CRISPR technology to European customers and co-founded BioXplor. Anna has been featured in Forbes as one of the "Women-led founders driving the future of HealthTech."

Pavels Kartasevs: Co-founder & CTO. A skilled engineer passionate about bioinformatics software development in genomics, proteomics, and metabolomics. Pavels holds an MEng in Computer Science from Riga Technical University and an MSc in Applied Bioinformatics from Cranfield University. He specializes in biological data classification and machine learning approaches using GPGPU-based predictive modeling.

Margo Soloshenko, PhD, MD: Chief Scientific Officer. A PhD graduate in Medical Science specializing in biomedical data analysis and pediatrics, proficient in Python and R. Margo has experience in clinical trials focusing on treatments for autoimmune diseases and has authored 45 medical articles and four books.

Kostiantyn Somin: Applications Developer. A professional developer with extensive experience in web technologies and application development. Kostiantyn holds a degree in Computer Science from the Ukraine Institute of Economic and Information Technologies, specializing in Programming and Automation of Computer Systems. With over 15 years of experience, he has mastered modern web technologies and popular frameworks for building progressive and high-performance mobile and web applications.

Scientific & Tech Advisory Board:

Dalila Belkhiri, MBA, MAS: Expertise in health innovation, digital health, medical devices, clinical global strategy, AI, deep tech, ethics, digital intelligence, healthcare in metaverse & nanoverse, and digital biomarkers.

Prof. Carlos Farkas Pool, PhD: Professor and Bioengineer in genetics and genomics from Universidad Católica de la Santísima Concepción, Chile. His research focuses on transcription factors involved in the progression of solid tumors in leukemia, with publications in top journals.

John Conway, MSc, PhD: Consulting Data Scientist with multi-industry experience in analytics, machine learning, and management.

Board of Directors:

Anna O'Leary: Co-founder & CEO.

David Kwon, MBA, MD, PhD: Studied at Harvard and Berkeley universities; Medical Director with over 20 years of industry experience (Novartis and Gilead), leading drug development and clinical trials in autoimmunity and cardiovascular therapeutics.

Bill Allison: Studied at Yale and UC Berkeley; Chief Technology Officer at the University of Berkeley. Leader in engineering, product management, emerging technology, and enterprise-wide digital transformation, expanding the use of cloud computing and implementing energy-efficient infrastructure supporting AI and data science research.

Todd Wallach, MSc, MBA, MSE: Entrepreneur, management consultant, board member, advisor, and seasoned senior executive in Biotechnology, Pharmaceuticals, Devices, Diagnostics, and Spacecraft & Space Systems. Todd has started and built innovative companies with market capitalization exceeding $2B, raised over $80M in capital, including $4.5M in grant funding, and has multiple exits with strong returns.

Competitor Profile

Market Insights and Dynamics:

The computational life sciences and digital health sectors are experiencing significant growth, driven by advancements in AI, machine learning, and data analytics. The increasing demand for personalized medicine and efficient drug discovery processes underscores the importance of innovative platforms like those developed by Arcella Bio.

Competitor Analysis:

While specific direct competitors to Arcella Bio are not detailed in the available information, companies operating in the digital health and computational life sciences space include:

Arcellx (ACLX): Focuses on developing innovative cell therapies for cancer treatment.

ARCA biopharma (ABIO): Specializes in developing genetically-targeted therapies for cardiovascular diseases.

Cabaletta Bio (CABA): Develops engineered T cell therapies for patients with B cell-mediated autoimmune diseases.

ArriVent BioPharma (AVBP): Concentrates on identifying and developing biopharmaceutical products.

These companies, while operating in related fields, have distinct focuses and product offerings compared to Arcella Bio's emphasis on data analytics platforms and patient empowerment applications.

Strategic Collaborations and Partnerships

Arcella Bio has engaged in significant collaborations to bolster its market position and innovation capacity:

European Commission Support: The Colorectal Cancer Patient App is co-funded and supported by the European Commission, highlighting a strategic partnership aimed at enhancing patient care.

EU Start-up Collaboration: Partnered with an innovative EU start-up to discover new combination therapies for colorectal cancer, demonstrating a commitment to collaborative research and development.

Operational Insights

Arcella Bio's strategic considerations include:

Market Position: By offering a comprehensive suite of products that integrate data analytics with patient empowerment tools, Arcella Bio positions itself uniquely in the computational life sciences sector.

Competitive Advantages: The company's proprietary technologies, such as its biomedical data infrastructure and scientific research engine, provide distinct competitive advantages by enabling rapid and accurate data analysis.

Strategic Opportunities and Future Directions

Arcella Bio's strategic roadmap includes:

Expansion of Product Offerings: Continued development of applications and platforms that address unmet needs in personalized medicine and drug discovery.